Ann: Third Quarter Results Presentation, page-2

Conclusions and Next Steps for Remestemcel-L in ARDS Due to COVID-19
▪ Remestemcel-L did not significantly reduce overall mortality
▪ Remestemcel-L reduced mortality and increased ventilator-free days through 60 Days in
pre-specified patient population < 65 years old
▪ Addition of remestemcel-L to dexamethasone was synergistic in reducing mortality and
increasing days alive off ventilator through 60 Days in exploratory analysis of patients < 65
▪ Plan to meet with U.S. Food and Drug Administration (FDA) to discuss potential next steps
▪ Confirmatory Phase 3 trial in COVID-19 ARDS patients < 65 years of age with
dexamethasone, explore additional remestemcel-L dosing regimens for patients with ARDS
≥ 65 years of age

Table 1 – Top Dexamethasone Manufacturers in the USA

List formed from information from company websites, mayoclinic.com, and marketwatch.com report: https://www.marketwatch.com/press-release/steroid-corticosteroids-market-2020-growth-analysis-share-and-consumption-by-regional-data-investigation-and-growth-demand-by-regions-types-and-analysis-of-key-players--research-forecasts-to-2024-2020-06-12?tesla=y

[1] https://www.macrotrends.net/stocks/charts/PFE/pfizer/revenue

[2] https://www.macrotrends.net/stocks/charts/NVS/novartis-ag/revenue

[3] https://www.merck.com/about/our-history/facts/home.html

[4] https://www.statista.com/statistics/266509/revenue-of-sanofi-since-2006/

[5] https://www.macrotrends.net/stocks/charts/BAX/baxter/revenue

[6] https://zyduscadila.com/public/pdf/financial/quarterly/Q2_2018_2019.pdf

[7] https://www.owler.com/company/endo

[8] https://www.forbes.com/companies/aspen-pharmacare-holdings/#4227695736ae

[9] https://www.hikma.com/investors/financial-information/

[10] https://www.cipla.com/about-us

[11] http://www.wockhardt.com/who-we-are/fact-sheet.aspx

Company

Headquarters

Year Founded

Annual sales

Pfizer

New York, NY

1849

$52 Bil [1]

Novartis

Basel, Switzerland

1996

$49.9 Bil [2]

Merck & Co.

Kenilworth, NJ

1891

$46.8 Bil [3]

Sanofi Pharmaceuticals

Paris, France

1973

$40 Bil [4]

Baxter International

Deerfield, IL

1931

$11.5 Bil [5]

Zydus Cadila

Ahmedabad, India

1951

$4.4 Bil [6]

Endo International

Dublin, Ireland

1997

$3 Bil [7]

Aspen Pharmacare Holdings

Durban, South Africa

1850

$2.8 Bil [8]

Hikma Pharmaceuticals

London, UK

1978

$2.2 Bil [9]

Cipla Limited

Mumbai, India

1935

$2.3 Bil [10]

Wockhardt Limited

Mumbai, India

1999

$1 Bil [11]

Xspire Pharmaceuticals

Madison, MS

2011

Private